Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations

Annals of Biomedical Engineering
Matthew T McKennaThomas E Yankeelov

Abstract

We develop a combined experimental-mathematical framework to investigate heterogeneity in the context of breast cancer treated with doxorubicin. We engineer a cell line to over-express the multi-drug resistance 1 protein (MDR1), an ATP-dependent pump that effluxes intracellular drug. Co-culture experiments mixing the MDR1-overexpressing line with its parental line are evaluated via fluorescence microscopy. To quantify the impact of population heterogeneity on therapy response, these data are analyzed with a coupled pharmacokinetics/pharmacodynamics model. The proliferation and death rates of each line vary with co-culture condition (the relative fraction of each cell line at the time of seeding). For example, the death rate in the parental line under low-dose doxorubicin treatment is increased from 0.64 (± 0.22) × 10-2 to 1.46 (± 0.58) × 10-2 h-1 with increasing fractions of MDR1-overexpressing cells. The growth rate of the MDR1-overexpressing line increases 29% as its relative fraction is decreased. Simulations of the pharmacokinetics/pharmacodynamics model suggest increased efflux from MDR1-overexpressing cells contributes to the increased death rate in the parental cells. Experimentally, the death rate of parental cells is c...Continue Reading

References

Oct 1, 1976·Science·P C Nowell
Feb 7, 2004·Science·Martin A Nowak, Karl Sigmund
Sep 2, 2004·Nature Reviews. Drug Discovery·Richard Weinshilboum, Liewei Wang
Nov 17, 2006·Nature Reviews. Cancer·Lauren M F MerloCarlo C Maley
Sep 27, 2007·Journal of the National Cancer Institute·Olivier TrédanIan F Tannock
Jan 11, 2008·Nature Reviews. Cancer·Eduardo Moreno
Sep 28, 2010·Trends in Cell Biology·Hongmei YuValerie M Weaver
Jul 8, 2011·Science Translational Medicine·Juliann ChmieleckiWilliam Pao
Sep 25, 2012·Cancer Research·Charles Swanton
Oct 16, 2012·Cancer Research·Ariosto S SilvaRobert A Gatenby
Apr 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Levi A Garraway
May 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rakesh K Jain
Jan 17, 2015·Cancer Research·Thomas E YankeelovErin C Rericha
Jan 21, 2015·Journal of Cellular Physiology·Peter L FrickVito Quaranta
Apr 8, 2015·Nature Medicine·Hyo-eun C BhangFrank Stegmeier
Nov 26, 2015·Nature Reviews. Cancer·Philipp M AltrockFranziska Michor
Mar 2, 2017·Proceedings of the National Academy of Sciences of the United States of America·Carlos Carmona-FontaineJoao B Xavier
Apr 25, 2017·Trends in Cancer·Boyang ZhaoDouglas A Lauffenburger

❮ Previous
Next ❯

Methods Mentioned

BETA
flow-cytometry
fluorescence microscopy

Software Mentioned

MATLAB

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.